Dr. Gilbert Tang/X
Nov 13, 2025, 01:15
Dr. Gilbert Tang Shares NEJM Late-Breaker: 7-Year Outcomes Reinforce TAVR as a Durable Option for Low-Risk Aortic Stenosis
Dr. Gilbert Tang, Vice Chair of Innovation, Cardiovascular Surgery Surgical and Academic Director at Mount Sinai Health System, shared a post on X:
“TCT2025 Late breaker PARTNER 3 Low Risk 7 Year Sapien3 TAVR vs SAVR showed no significant differences in composite endpoint, all-cause mortality, CV mortality, and low reintervention rates in both arms. Clinical valve thrombosis 2.8% TAVR vs 0.5% SAVR but similar BVF (valve failure) and reintervention.
Paper now online The New England Journal of Medicine (NEJM)
and can download here.

Nice TCTMD article.”
Stay updated with Hemostasis Today.
-
Feb 23, 2026, 13:02Deepak Yadav: What 2025 Evidence Tells Us About Stroke Care
-
Feb 23, 2026, 12:55Radoslaw Kaczmarek: Will AAV Gene Therapy for Hemophilia Trigger Tumorigenesis?
-
Feb 23, 2026, 12:46Heghine Khachatryan: More Granular Risk Stratification Framework for PE from The New 2026 AHA/ACC Guideline
-
Feb 23, 2026, 12:37Reza Shojaei: EU’s Critical Medicines Act and Plasma Resilience
-
Feb 23, 2026, 12:32Anirban Sen Gupta: Emily Mihalko Highlights PlateChek at MTEC
-
Feb 23, 2026, 12:25Ryan Williams: Excellent Highlights on The Heterogeneity of PRP Preparation
-
Feb 23, 2026, 12:10Peter Libby: hsCRP May Select Patients Who Can Benefit From Statins or Anti-inflammatory Therapy
-
Feb 23, 2026, 12:02Marios Georgakis: An Unprecedented for An Antithrombotic Therapy from OCEANIC-STROKE Trial
-
Feb 23, 2026, 11:37Charles Okyere Boadu: Blood Donation Helps Lower Your Risk of Stroke and Organ Damage